The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients

Wang, Bing‐Yen; Huang, Jing‐Yang; Chen, Heng-Chung; Lin, Ching‐Hsiung; Lin, Sheng‐Hao; Hung, Wei-Heng; Cheng, Ya‐Fu

doi:10.1007/s00432-019-03079-8

Cited by 139 publications

(110 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have observed marked differences on clinicopathology, chemotherapeutic responses and prognosis between lung squamous cell carcinoma and adenocarcinoma patients [3]. Notably, the overall survival time in patients with SQC is much shorter than that in patients with ADC [3,4]. Therefore, it is of great necessity to identify the underlying molecular mechanism in SQC, which would be helpful for developing an effective therapeutic strategy against SQC.…”

Section: Introductionmentioning

confidence: 99%

LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression

et al. 2020

View full text Add to dashboard Cite

Background Anti-angiogenic therapy represents a promising strategy for non-small-cell lung cancer (NSCLC) but its application in lung squamous cell carcinoma (SQC) is limited due to the high-risk adverse effects. Accumulating evidence indicates that long noncoding RNAs (lncRNAs) mediate in tumor progression by participating in the regulation of VEGF in NSCLC, which might guide the development of new antiangiogenic strategies. Methods Differential lncRNA expression in SQC was analyzed in AE-meta and TCGA datasets, and further confirmed in lung cancer tissues and adjacent normal tissues with RT-qPCR and in-situ hybridization. Statistical analysis was performed to evaluate the clinical correlation between LINC00173.v1 expression and survival characteristics. A tube formation assay, chick embryo chorioallantoic membrane assay and animal experiments were conducted to detect the effect of LINC00173.v1 on the proliferation and migration of vascular endothelial cells and tumorigenesis of SQC in vivo. Bioinformatics analysis, RNA immunoprecipitation and luciferase reporter assays were performed to elucidate the downstream target of LINC00173.v1. The therapeutic efficacy of antisense oligonucleotide (ASO) against LINC00173.v1 was further investigated in vivo. Chromatin immunoprecipitation and high throughput data processing and visualization were performed to identify the cause of LINC00173.v1 overexpression in SQC. Results LINC00173.v1 was specifically upregulated in SQC tissues, which predicted poorer overall and progression-free survival in SQC patients. Overexpression of LINC00173.v1 promoted, while silencing LINC00173.v1 inhibited the proliferation and migration of vascular endothelial cells and the tumorigenesis of SQC cells in vitro and in vivo. Our results further revealed that LINC00173.v1 promoted the proliferation and migration of vascular endothelial cells and the tumorigenesis of SQC cells by upregulating VEGFA expression by sponging miR-511-5p. Importantly, inhibition of LINC00173.v1 via the ASO strategy reduced the tumor growth of SQC cells, and enhanced the therapeutic sensitivity of SQC cells to cisplatin in vivo. Moreover, our results showed that squamous cell carcinoma-specific factor ΔNp63α contributed to LINC00173.v1 overexpression in SQC. Conclusion Our findings clarify the underlying mechanism by which LINC00173.v1 promotes the proliferation and migration of vascular endothelial cells and the tumorigenesis of SQC, demonstrating that LINC00173.v1-targeted drug in combination with cisplatin may serve as a rational regimen against SQC.

show abstract

Section: Introductionmentioning

confidence: 99%

LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The histology of squamous cancers demonstrated a prominent significance with positive survival benefits compared with nonsquamous cancers, indicating that histology could be a protective factor. Another explanation considers it could be the mortality from cancer and its poor prognosis compared with other types of histology (21,22). This study has several limitations.…”

Section: Discussionmentioning

confidence: 91%

Overall Survival in Heart Disease–Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study

et al. 2020

View full text Add to dashboard Cite

The cardiotoxicity during immunotherapy administration leads to mortality by more than 42% and heart disease-related mortality among immunotherapy-linked cancers is still considered to be underestimated. In this study, the advanced stage of non-small cell lung cancer (NSCLC) with heart disease-related death was selected in accordance with immunotherapy approval time. NSCLC was searched on the Surveillance, Epidemiology, and End Results (SEER) program. Results show that 538 advanced NSCLC cases, those dominated by men and elderly people aged more than 70 years, had a high percentage of heart disease-related death in both eras. The difference between contemporary groups was fairly nonsignificant (P = > 0.05). The overall survival (OS) of allcause mortality difference showed improved survival in the immunotherapy group (P = 0.0001). In the study of heart disease-related death survival with adjusted data, the NSCLC patients show significant lower survival in the immunotherapy era compared with the nonimmunotherapy era (P = 0.003; hazard ratio [HR] = 1.31; 95% CI = 1.099-1.57). In the multivariate analysis of NSCLC-related immunotherapy, histology revealed that the non-squamous cell type had an independent risk for lower OS than the squamous cell type (P = 0.04; HR= 0.74; CI = 0, 55-0.99). The results demonstrate the survival benefits for NSCLC in immunotherapy; however, in heart disease-related death, immunotherapy in patients with NSCLC shows decreased OS. This study highlights that NSCLC patients should be highly monitored during immunotherapy administration, and further assessment is needed.

show abstract

“…Despite the great improvement has been achieved in lung cancer screening and personalized treatment modalities (precision medicine) in current years, the 5-year survival rates still remain dismal. As for stage I, the 5-year survival probability is 68-92%, while for stage IV, it decreased to 0-10% [6,7]. Therefore, exploring a prognostic molecular signature and developing a prediction nomogram are essential for selecting the optimum therapeutic strategies and improving the adverse prognosis for lung ADC patients.…”

Section: Introductionmentioning

confidence: 99%

Construction of a m6A RNA Methylation Regulator-related Signature for Prognosis and Immune Response in Lung Adenocarcinoma

Sheng

Xia

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundN6-methyladenosine (m6A) RNA methylation is related to cancer pathogenesis and development. However, few studies have investigated the role of m6A regulator genes in lung adenocarcinoma (ADC).MethodsGene expressions with clinicopathological data were downloaded from The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO) database. We compared the expression of twenty m6A regulator genes between tumor and normal samples. Univariate and least absolute shrinkage and selection operator (LASSO) Cox regression model were used to derive a multi-gene signature. A signature-based nomogram was developed, and the prediction performance was validated by an exterior validation set (GSE72094). Weighted gene co-expression network analysis (WGCNA) was performed to construct a co-expression network and identify the hub genes. The association of m6A signature with immunity was examined.ResultsSeventeen differentially expressed genes were identified. A five-gene prognostic signature (IGF2BP1, IGF2BP2, HNRNPA2B1, METTL3, and HNRNPC) was determined, and demonstrated as an unfavorable prognostic factor. A signature-based nomogram was developed to predict each patient’s survival probability, and the nomogram was well calibrated and showed a satisfactory discrimination. Turquoise was identified as the most risk-related module, and genes in this module were enriched in the pathway of cell cycle. Six genes were determined as the hub genes. High-risk patients had significantly higher expression of PD-L1, higher tumor mutational burden (TMB), higher proportion of immune checkpoint blockade (ICB) response, and lower proportion of T cells CD8.ConclusionsIn summary, the signature-based nomogram is useful for survival prediction, and high-risk patients were more sensitive to the ICB therapy.

show abstract

The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients

Cited by 139 publications

References 37 publications

LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression

LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression

Overall Survival in Heart Disease–Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study

Construction of a m6A RNA Methylation Regulator-related Signature for Prognosis and Immune Response in Lung Adenocarcinoma

Contact Info

Product

Resources

About